Just two years ago, the merger of Ivac and Imed that created Alaris Medical seemed a last-ditch effort against entrenched industry giants Baxter and Abbott, which were offering customers an IV solutions-pump bundle that threatened Ivac's and Imed's stand-alone technology. Alaris Medical has successfully fought off its much larger competitors, winning important contract positions at many of the leading hospital purchasing groups . But the recent trend toward toward consolidation in medical supplies has company officials worried because Alaris's prospects for growth in its core business are limited.
You may also be interested in...
To build a “reliable long-term domestic production” of medicines and related supplies and to “minimize potential shortages,” US President Donald Trump has signed a ‘Buy American’ executive order. However, the move has left industry wondering if it is a sustainable solution.
The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.
Big pharma has faced many evolutions to the pharma playbook of old. New technologies such as wearables introduce behavioral change to patients, while e-commerce giants such as Amazon seek a piece of the Rx action. The health care industry has done a reasonable job of weathering the storm inflicted on its core business model over the years, but it has yet to be a true disruptor. As the world marches on is pharma’s choice to disrupt, or inevitably be disrupted for good?